# DESCRIPTION

## STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

- disclose government rights in invention

## BACKGROUND OF THE INVENTION

- describe sPLA2-IIA role in inflammatory diseases

## BRIEF SUMMARY OF THE INVENTION

- introduce method for identifying integrin-sPLA2-IIA binding inhibitors
- describe method for treating inflammatory conditions
- outline composition and kit for treating inflammatory conditions

## DEFINITIONS

- define inflammation and inflammatory response
- define inflammatory condition
- define sPLA2-IIA protein and polynucleotide
- define integrin chains αv, α4, β1, and β3
- define inhibitors of sPLA2-IIA and integrin binding
- define composition consisting essentially of a sPLA2-IIA-integrin binding inhibitor
- define inactivating antibody
- define effective amount or therapeutically effective amount
- define subject or subject in need of treatment
- define nucleic acid or polynucleotide
- define target nucleic acid
- define polypeptide, peptide, and protein
- define amino acid
- define antibody
- define specific binding to an antibody

## DETAILED DESCRIPTION OF THE INVENTION

### I. Introduction

- introduce phospholipase A2 family
- describe biological effects of sPLA2-IIA
- discuss catalytically inactive sPLA2-IIA mutants
- propose sPLA2-IIA's action through interaction with specific receptors
- introduce integrins as receptors for sPLA2-IIA

### II. Recombinant Expression of Polypeptides

- introduce general recombinant technology
- describe oligonucleotide synthesis
- discuss polynucleotide sequence verification
- introduce cloning and subcloning of coding sequences
- describe PCR-based cloning approach
- discuss isolation of full-length coding sequences
- introduce modification of polynucleotide coding sequences
- describe conservative substitutions and truncations
- discuss mutational methods for generating diversity
- introduce modification of nucleic acids for preferred codon usage
- describe chemical synthesis of polypeptides

### III. Expression and Purification of Recombinant Polypeptides

- describe expression systems
- motivate bacterial promoters
- describe eukaryotic expression systems
- outline expression vector components
- discuss transcription termination regions
- list bacterial expression vectors
- list eukaryotic expression vectors
- describe gene amplification markers
- outline high yield expression systems
- describe transfection methods
- outline purification of recombinantly produced polypeptides
- describe purification from bacterial inclusion bodies
- describe purification from bacterial periplasm
- outline standard protein separation techniques
- describe column chromatography

### IV. Inhibitors of sPLA2-IIA and Integrin Binding

- introduce inhibitory nucleic acids
- define inhibitory nucleic acids
- describe mechanisms of inhibitory nucleic acids
- classify inhibitory nucleic acids
- describe RNA aptamers
- introduce inactivating antibodies
- describe inactivating antibody fragments
- describe chimeric antibodies
- introduce identification of sPLA2-IIA and integrin binding inhibitors
- describe cell-based screening assays
- describe in vitro binding assays
- describe combinatorial chemical libraries
- describe preparation and screening of combinatorial chemical libraries
- describe alternative methods for identifying inhibitors

### V. Inflammatory Responses and Conditions

- describe inflammatory responses
- describe inflammatory conditions

### VI. Pharmaceutical Compositions and Administration

- introduce pharmaceutical compositions
- describe routes of administration
- describe pharmaceutical carriers
- describe solid dosage forms
- describe liquid pharmaceutical compositions
- describe administration for prophylactic and therapeutic treatments

### VII. Therapeutic Applications Using Nucleic Acids

- introduce therapeutic approaches
- discuss gene therapy
- describe vectors for nucleic acid delivery
- define gene delivery systems
- discuss viral vector systems
- describe retroviral vectors
- explain design of retroviral vectors
- discuss packaging cell lines
- describe pharmaceutical formulations
- discuss administration of formulations
- determine effective dosage

### VIII. Kits

- describe kits for treating inflammatory conditions

## EXAMPLES

- provide examples of experimental procedures

### Experimental Procedures

- synthesize recombinant soluble αvβ3
- express human β3 in CHO pgs745 mutant cells
- synthesize sPLA2-IIA as an insoluble protein in bacteria BL21
- perform site-directed mutagenesis by QuickChange method
- remove endotoxin from sPLA2-IIA

### Results

- show sPLA2-IIA binds to integrin αvβ3
- demonstrate soluble sPLA2-IIA binds to cell surface αvβ3
- show recombinant soluble αvβ3 binds to immobilized sPLA2-IIA
- perform docking simulation of interaction between sPLA2-IIA and integrin αvβ3
- introduce mutations within the predicted interface of sPLA2-IIA with integrin αvβ3
- determine binding kinetics of wt and mutant sPLA2-IIA to soluble αvβ3
- measure PLA2 activity
- show sPLA2-IIA-induced proliferation of monocytic cells in an integrin-dependent manner
- map the sPLA2-IIA binding site in the α4 subunit

### Discussion

- establish sPLA2-IIA binding to integrin αvβ3
- describe integrin αvβ3 expression and role in diseases
- present evidence for sPLA2-IIA binding to α4β1 and integrin-dependent cell proliferation
- suggest sPLA2-IIA-integrin interaction as a therapeutic target

